Sinovac Biotech Ltd, a leading provider of biopharmaceutical products in China, announced that the Ministry of Industry and Information Technology of the People's Republic of China has issued the initial order to Sinovac to purchase H1N1 vaccine for the national stockpiling plan. According to the initial order, Sinovac is required to complete the production of 3.3 million doses of Panflu (15ug/0.5ml), the H1N1 vaccine manufactured by Sinovac, before September 15, 2009. Two doses of the vaccine are packaged in one vial.

Sinovac initiated the production of H1N1 vaccine on June 15, 2009 and initiated the clinical trial on July 22. On August 17, Sinovac announced its top-line positive results of H1N1 vaccine clinical trials, in which the vaccine showed good safety and immunogenicity profiles after one shot. Following the positive results of an experts' evaluation conference organized by the State Food and Drug Administration (SFDA), on September 3, 2009, Sinovac obtained the production license from the SFDA for Panflu, Sinovac's H1N1 vaccine.

Weidong Yin, chairman, president and CEO of Sinovac, commented, "Sinovac has been aiming to provide Chinese children with international- quality vaccines and provide children throughout the world with vaccines made in China, and to fulfil our mission of supplying vaccines to eliminate human diseases. Sinovac is very glad to be supplying our H1N1 vaccine to the Chinese government and we are confident that we can complete the national H1N1 vaccine stockpiling task in a timely manner."

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases.